Trifexis

Quick links to important sections

Trifexis

Method of action: Endectocides

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trifexis

Property Description
Active Ingredients Milbemycin Oxime, Spinosad
Manufacturer Elanco
Form Oral Chewable Tablet (Beef-Flavored)
Pharmacological Class Endectocide; Antiparasitic Agent
Target Audience Dogs and Puppies (8+ weeks, 5+ lbs)
Status Prescription-Only Drug (Rx)

What is Trifexis and What is its Classification?

Trifexis is a prescription-only veterinary medicine manufactured by Elanco and specifically developed for the canine species. It is officially defined as a fixed-dose combination product because it unites two distinct active ingredientsMilbemycin Oxime and Spinosad—within a single dosage unit. This combined action positions the drug within the high-level pharmacological class of endectocides, a category recognized for agents that target both internal and external parasites simultaneously.

Composition and Unique Form

The medicine contains Milbemycin Oxime, a semi-synthetic compound of the macrocyclic lactone class, and Spinosad, which is uniquely derived from the fermentation products of the soil bacterium Saccharopolyspora spinosa. The unique pairing provides a dual mechanism of action that is clinically recognized for rapidly disrupting the nervous systems of susceptible parasites. The product is physically presented as an oral chewable tablet, a distinguishing feature that ensures complete internal delivery of the dose, supported by the beef-flavored design to aid oral administration compliance.

General Purpose and Efficacy Type

The general purpose of this dual-action agent is to achieve robust broad-spectrum control by leveraging the distinct strengths of its components. In this combination, Spinosad targets fleas, while Milbemycin Oxime prevents heartworm disease and eliminates various intestinal worms. The intended efficacy is based on the principle of neurological disruption leading to the parasite's swift paralysis and subsequent death.

Regulatory References

  1. FDA NADA 141-321

What side effects are possible with Trifexis?

Possible Side Effects and Safety Information

The official safety profile for this fixed-dose combination veterinary medicine is structured around documented adverse reactions and specific regulatory constraints, primarily concerning the Gastrointestinal and Nervous Systems, as documented by regulatory agencies such as the FDA and EMA.

Documented Adverse Reactions by Frequency

The regulatory classification of adverse reactions is based on observed occurrence rates in studies and surveillance:

  • Common Reactions: These frequently observed effects include vomiting (often noted within the first 48 hours after administration), diarrhea, lethargy, anorexia (decreased appetite), and reactions affecting the skin, such as pruritus (itching) and localized reddening.
  • Uncommon Reactions: Less frequent but officially documented reactions primarily involve the Nervous System, including muscle tremors, ataxia (incoordination), and seizures.
  • Very Rare Reactions: Post-marketing reports have documented, in very rare cases, severe outcomes such as blindness or other impaired vision.

Population-Specific Safety Constraints

Specific cautions are defined for certain populations and conditions. Prior to initiating treatment, animals must be tested for existing heartworm infection. The medicine is explicitly not effective against adult heartworms. Furthermore, official regulatory documents advise caution when using the product in dogs with a history of pre-existing epilepsy and in those with the MDR-1 gene mutation due to increased risk of neurological adverse events. The safety profile has not been sufficiently established for use in pregnant, lactating, or breeding males.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Trifexis (Spinosad and Milbemycin Oxime) documents severe signs related to the Central Nervous System and Gastrointestinal System following high exposure. Overdose studies have documented clinical manifestations up to five times the maximum recommended dose.

Overdose Presentation Key Clinical Manifestations
Neurotoxic Seizures, Tremors or shaking, Ataxia (loss of coordination), and Vocalization.
Gastrointestinal/Systemic Vomiting (frequent), Salivation, Diarrhea, Lethargy, and Anorexia.

Emergency Action and Required Help

Official regulatory information mandates that the owner contact a veterinarian as soon as possible if a suspected ingestion exceeds the recommended dose. Immediate medical help is required when severe neurological signs, such as seizures or marked ataxia, are observed. Management of an overdose is restricted to symptomatic and supportive treatment, as no specific antidote is known according to the official labeling.

Specific Considerations

Caution is noted for use in dogs with pre-existing epilepsy due to the increased risk of neurological events. Transient hypersensitivity reactions may also occur in heartworm-positive dogs due to the drug’s components.

Therapeutic Uses of Trifexis

What Trifexis Treats: Main Uses and Benefits

The medicine is applied across multiple domains where additional symptomatic support and prophylaxis are needed. It is commonly used to help manage three core categories of parasitic threats.

The core therapeutic application is prophylaxis against systemic heartworm disease. Beyond this critical prophylactic role, it is relevant for the management of flea infestations and the treatment and control of adult intestinal parasites, specifically hookworms, roundworms, and whipworms.

Prevention of Systemic Heartworm Disease

This is the primary prophylactic domain of use. The medication is generally applied consistently to help protect against heartworm infection, which is a severe systemic condition. Consistent monthly use supports general well-being and is applied consistently to help reduce the risk associated with this severe systemic condition that may cause significant systemic damage if established.

“Applied consistently, this medication is relevant for managing the patient's exposure to common parasitic health threats.”

Relief from Flea Infestation and Skin Distress

The medicine is used for both the treatment and ongoing prevention of flea infestations, including conditions where symptoms are related to inflammatory or irritative states like Flea Allergy Dermatitis (FAD). It helps address the source of external parasitic burden, which helps address symptom clusters that may become intense, such as pruritus (itching) and redness, and subsequent skin inflammation. This contributes to improved day-to-day comfort and helps ease symptoms that may create noticeable functional strain.


Quick Fact: Relief for Dermal Discomfort

Quick Fact: Relief for Dermal Discomfort

Action against adult fleas helps ease symptoms related to inflammatory or irritative states, contributing to improved day-to-day comfort by lessening the burden of intense itching and skin irritation.


Control of Gastrointestinal Nematode Infections

Trifexis is relevant for the management of three adult internal parasites: hookworms, roundworms, and whipworms. By targeting these common intestinal worms, it is applied in addressing associated symptoms like diarrhea and weight loss, and helps support functional stability by easing the overall symptom burden.

Regulatory References

  1. Official NIH DailyMed Drug Label

Eligibility and Restrictions for Use

Who Can and Cannot Use Trifexis?

This section defines the official population eligibility for Trifexis, strictly according to government regulatory labeling.

Eligibility Scope

Category Regulatory Status
Target Species Dogs and Puppies
Minimum Age 8 weeks of age or older
Minimum Weight 5 pounds of body weight or greater

Contraindications and Conditional Use

Contraindicated Populations: The product is explicitly labeled “Not for Human Use” and is strictly for veterinary application. There are no known absolute contraindications listed on the official label for the target species, dogs.

Condition-Specific Restrictions:

  • Dogs with an existing adult heartworm infection are not eligible for use until the infection is cleared with an adulticide treatment.
  • Dogs with pre-existing epilepsy or a history of seizure disorders are designated for conditional use with caution.

Reproductive Status:

  • Use in breeding females (pregnant or lactating) is labeled for conditional use with caution.
  • Safety has not been evaluated and is not established in breeding males.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define the interaction profile of Trifexis based on its active ingredients, Milbemycin Oxime and Spinosad. There are no known contraindications listed in the prescribing information for co-administration with other medicinal products.

Transporter- and Exposure-Related Interactions

Both active ingredients are classified as P-glycoprotein (P-gp) substrates. This classification indicates a potential for transporter-mediated interaction when the medicine is used concomitantly with other P-gp substrates, such as digoxin or doxorubicin. This co-administration may lead to an increase in systemic exposure of the active components, which may result in enhanced toxicity according to regulatory reports. Furthermore, official data notes that repeated monthly dosing is associated with evidence of accumulation of both active components in the bloodstream.

Pharmacodynamic Interaction Risk

A specific pharmacodynamic interaction risk is documented with the extra-label co-administration of ivermectin, which is another macrocyclic lactone. This interaction has been associated with post-marketing reports of severe neurological signs, including trembling, ataxia, and seizures. The risk of adverse effects from this type of interaction is formally noted as being heightened in dogs that carry the MDR-1 gene mutation (avermectin-sensitive dogs). Regulatory documents do not specify any mandatory timing separation rules for co-administered medicinal products.

Mechanism of Action

Mechanism of Action: Dual Neurological Attack

The drug functions through two distinct, complementary mechanisms targeting the invertebrate nervous system. The Spinosad component operates as an allosteric agonist of specific Nicotinic Acetylcholine Receptors ( nAChRs) in insect motor neurons. This binding causes prolonged depolarization, resulting in the uncontrolled, high-rate firing of motor neurons. This cascade of neural hyperexcitation culminates in severe, involuntary muscle contractions and subsequent systemic paralysis.

The Milbemycin Oxime component targets Glutamate-Gated Chloride Channels ( GluCl channels) found in susceptible helminths. It acts as a direct agonist, forcing these channels to remain open, which facilitates a massive influx of chloride ions ( Cl-). This ion flux drives the nerve and muscle cells into a state of profound hyperpolarization (cellular shutdown), causing a complete blockade of neuromuscular signaling that results in irreversible flaccid paralysis.

Safety is conferred by selective toxicity; GluCl channels are absent in mammals, and host P-glycoprotein efflux pumps actively restrict Milbemycin Oxime's movement into the host's central nervous system, limiting the mechanism's scope to target organisms.

Dosage and Administration Information

How to Use Trifexis

The administration of Trifexis (spinosad and milbemycin oxime) is based on a monthly dosing schedule and specific intake conditions. The medicine is provided as a chewable tablet and is intended exclusively for oral administration.


Administration Scope and Dosing

The dosage is determined by the patient’s body weight, utilizing one whole tablet from five available strengths to meet the minimum dose of 13.5 mg/lb (30 mg/kg) spinosad and 0.2 mg/lb (0.5 mg/kg) milbemycin oxime.

Feature Administration Summary
Route of Administration Oral administration only.
Dosing Frequency Once a month at regular monthly intervals.
Timing with Meals Must be administered with food (a full meal) for maximum effectiveness.
Minimum Use Limits Approved for dogs and puppies 8 weeks of age or older and weighing 5 pounds or greater

Procedural Use Protocol

The usage protocol is designed to ensure the full dose is absorbed. The tablet must be administered with food. If a dog vomits within one hour of administration, a full replacement tablet must be given immediately. Following administration, the dog should be observed for one hour to confirm consumption and retention of the dose.

For continuous heartworm prevention, monthly administration must be continued for at least three months after the patient's last exposure to mosquitoes. If a regular dose is missed, it must be administered immediately with food, and the regular monthly schedule must then be resumed.

Recent Clinical Evidence

Overview of Clinical Trials

Clinical data for the combination of spinosad and milbemycin oxime (Trifexis) primarily focuses on its use in dogs for the prevention of heartworm disease and the treatment of flea infestations and intestinal parasites. Trials conducted to support the efficacy of the product are typically randomized, blinded, and controlled studies.

Efficacy Against Parasites

  • Heartworm Prevention: Laboratory studies have investigated the effectiveness of the milbemycin oxime component against induced infections of Dirofilaria immitis (heartworm) larvae. These studies demonstrated a high level of prevention against subsequent heartworm infection, with efficacy reaching 100% in many trials when administered at the specified monthly interval.
  • Flea and Intestinal Nematodes: Field and laboratory trials have evaluated the combination's impact on natural flea infestations (Ctenocephalides felis) and various intestinal worm infections (e.g., Toxocara canis, Ancylostoma caninum). Studies have indicated substantial reductions in flea counts and high effectiveness in reducing fecal egg counts for targeted nematodes.

Safety and Pharmacokinetics

Target animal safety studies have been conducted in dogs, including evaluations up to multiple times the recommended dose. These studies assessed safety over extended periods, with some adverse events reported, such as transient vomiting, which is a known effect of the components.

Research has explored the pharmacokinetics of the two active substances administered together. The co-administration of spinosad has been observed to alter the systemic exposure of milbemycin oxime compared to when the latter is given alone. Regulatory assessments concluded that this increased exposure, at the recommended dose, does not lead to clinically significant safety concerns in healthy dogs.

Frequently Asked Questions (FAQ)

Common questions about Trifexis (FAQ)


Q: Does Trifexis also help with ticks?

Official regulatory documents indicate that Trifexis is approved for the prevention and treatment of fleas, heartworm disease, and specific intestinal parasites, including hookworm, roundworm, and whipworm. Ticks are not listed among the parasites for which the medicine is officially indicated in the approved labeling.


Q: How quickly does Trifexis start working after giving it?

Studies supporting the medicine's effectiveness show that the spinosad component begins to affect fleas within 30 minutes of administration. In controlled laboratory settings, the medicine achieved 100% effectiveness against fleas within four hours of being given.


Q: How long does one dose of Trifexis last?

Trifexis is approved for administration once a month. The official labeling specifies a monthly dosing interval for the prevention of heartworm disease and the prevention and treatment of external and internal parasites.


Q: Can Trifexis be split in half if the tablet is too big?

The official administration guidelines for the dosage of Trifexis specify that dogs should receive one whole tablet corresponding to their weight band. The regulatory labeling does not include specific instructions for splitting the tablet.


Q: Is it better to give Trifexis with a full meal or just a snack?

The product label states that the medicine must be administered with food (a full meal) for maximum effectiveness. This requirement is in place for maximum effectiveness, which is tied to proper absorption.


Q: What if my dog spits out the Trifexis tablet?

The official protocol advises that the dog should be observed for one hour after administration to ensure the dose is consumed and retained. If the tablet is spat out and not consumed, the product's protocol for vomiting within one hour defines that a full replacement dose should be re-administered immediately.


Q: Are there generic alternatives to Trifexis?

Trifexis is the brand name for the fixed-dose combination of the active ingredients spinosad and milbemycin oxime. Regulatory records define it as a specific brand-name product. The existence of generic alternatives with the identical fixed-dose combination and indications is not specified on the primary label.


Q: Can Trifexis affect a dog's mood or behavior?

The official safety profile lists several nervous system-related effects reported during trials and post-marketing surveillance. These include common effects such as lethargy or decreased activity, and less common effects like trembling or seizures. Effects on mood or broader behavior are not explicitly detailed in the adverse reaction listings.


Q: Does the evidence support using Trifexis year-round?

Official documentation requires the medicine to be given once a month at regular intervals. For heartworm prevention, administration is specified to continue for at least three months after the last exposure to mosquitoes. This requirement suggests the need for continuous use in areas where mosquito exposure is prolonged.


Q: Can Trifexis be given to a dog taking antibiotics?

The official regulatory documents state there are no known contraindications listed for the use of Trifexis. The warnings focus on specific drug classes (P-gp substrates, certain macrocyclic lactones) with known interaction potential, but antibiotics are not specified as a restricted class.


Q: Are there any herbs or supplements that should not be given with Trifexis?

The official drug interaction warnings are focused on co-administration with other prescription veterinary medicines that affect drug transport or neurological systems. Herbs or supplements are not specifically addressed in the regulatory interaction profile documented on the product label.


Q: How is Trifexis different from a topical flea treatment?

Trifexis is officially classified as an oral chewable tablet that works systemically after being swallowed and absorbed into the bloodstream. This method of action is distinct from topical treatments, which are applied externally to the animal’s skin.


Q: Does Trifexis need to be given on the exact same day every month?

The official instruction requires that the medicine be administered once a month at regular monthly intervals. The protocol for a missed dose shows the priority is resuming the regular monthly interval as quickly as possible.


Q: Is it normal for a dog to be a little tired after the first dose?

The official safety profile lists lethargy or decreased activity as a common adverse reaction reported during clinical trials and post-marketing surveillance. This finding is a known, general effect of the medicine.


Q: What are the symptoms of a serious allergic reaction to Trifexis?

The product label lists uncommon and very rare adverse reactions that can be severe, including tremors, seizures, blindness, or impaired vision. The official documentation does not use the specific term 'allergic reaction' to define a category of adverse events.


Q: Can Trifexis interact with pain medication?

The regulatory warnings focus on potential interactions with P-glycoprotein substrates and other macrocyclic lactones. Pain medication is not specifically mentioned as a restricted class on the official label.


Q: Does the body weight of the dog determine the likelihood of side effects from Trifexis?

Dosage is strictly determined by body weight to ensure the appropriate amount is administered. While the label notes that puppies less than 14 weeks of age may experience a higher rate of vomiting, it does not make a general claim that side effect likelihood is based on an individual dog's weight within the approved dosing range.


Q: Does Trifexis prevent intestinal parasites other than the ones listed?

The official indications state that the medicine is for the treatment and control of adult hookworm, adult roundworm, and adult whipworm. Other intestinal parasites are not listed in the approved labeling.


Q: Are there warnings about Trifexis use in certain environments or climates?

The instructions for heartworm prevention require monthly administration for at least three months after the last exposure to mosquitoes. This requirement links the administration schedule to environmental factors that influence parasite exposure, but the label does not specify climate-based restrictions.


Q: Can Trifexis be shipped or does it need special storage?

Official storage instructions require the medicine to be kept at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). Brief excursions are permitted, but the product must be protected from moisture and kept in its original container.


Q: Why are there different colors for the Trifexis packages?

The official labeling specifies that there are five different strengths of the tablet, each corresponding to a specific dog weight band. The different colors are used as a visual aid to distinguish between the five different weight-based dosage sizes.


Q: Does Trifexis have any effect on ear mites or mange?

The official label lists the specific parasites for which Trifexis is indicated: fleas, heartworm, hookworms, roundworms, and whipworms. Ear mites or mange are not listed among the indications on the primary regulatory document.


Q: If a dog has a known health condition, who decides if Trifexis is appropriate?

Trifexis is a prescription-only medicine. The use of the drug in an animal with a pre-existing health condition, such as epilepsy or a heartworm-positive status, is a decision that requires the authorization and direction of a licensed veterinarian.


Q: What happens if a dog gets an overdose of Trifexis?

Regulatory safety studies evaluated use at up to ten times the recommended dose. The label states that signs of overdose that may occur include vomiting. The label notes that for suspected overdose, immediate consultation with a veterinarian is necessary.


Q: Can a dog switch from a different flea/heartworm medicine to Trifexis easily?

The label does not detail specific switching protocols but requires that dogs be tested for existing heartworm infection prior to starting treatment. This testing is a mandatory step before initiating therapy regardless of prior treatment.


Q: What happens if a dose of Trifexis is missed?

If a dose is missed, the official protocol is to administer the missed dose with food as soon as possible and immediately resume the regular monthly dosing schedule.


Q: Does Trifexis eliminate all stages of the flea life cycle?

The regulatory documents state that Trifexis is indicated for the treatment and prevention of flea infestations. The efficacy is primarily measured by the rapid killing of adult fleas and the prevention of subsequent infestations.


Q: Is Trifexis safe for small breed dogs?

Trifexis is approved for dogs and puppies weighing 5 pounds or greater. The smallest dosage size is specifically for dogs weighing 5 to 10 pounds. There are no breed-specific restrictions listed on the official label.


Q: Can Trifexis be used in breeding dogs?

The official label advises use with caution in breeding females. The document also states that the safe use of Trifexis in breeding males has not been evaluated and is not established.

How should Trifexis be stored and disposed of?

Storage and Disposal Requirements for Trifexis

Mandatory Storage Conditions

Requirement Official Statement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Brief excursions between 15 C and 30 C (59 F and 86 F) are permitted.
Protection Must be protected from moisture.

Handling and Safety

Trifexis must be kept in its original container and should remain sealed within the blister packaging until the moment it is ready for use. The regulatory labeling requires that the product be stored out of the reach of children.

Disposal Instructions

When disposing of the unused product or any waste material, the official labeling requires that disposal be carried out in accordance with local requirements. These instructions ensure the medicine is discarded safely, following standard pharmaceutical waste procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trifexis found in:

A-Z Index: